Treventis was well represented at the Alzheimer Association International Conference, running from Jul 14-18, 2019, in Los Angeles, California. In attendance were CEO Christopher Barden, VP Research Marcia Taylor, and Chief Medical Officer Dr. Donald Weaver.
Dr. Weaver presented a poster entitled “Efficient Computational Algorithms for Predicting Brain Permeability and Effect of Transporters.” In this work, Dr. Weaver’s research group – in collaboration with Treventis founders Christopher Barden and Mark Reed – explored how further advances in computational techniques could more accurately model important pharmacologic properties. This work has the potential to reduce the reliance on direct measurement of blood-brain barrier permeability in vivo, accelerating the work flow in CNS drug discovery programs.